Cipla Limited has informed the Exchange regarding 'Update on USFDA inspection at facility of Sitec in Mahape, Navi Mumbai, India'.
CIPLA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Cipla has informed the exchanges that the USFDA has classified its inspection of Sitec Labs Limited's analytical testing facility in Mahape, Navi Mumbai as Voluntary Action Indicated (VAI). The inspection took place from 18th to 20th February 2025, and the USFDA communicated this classification via email on 16th May 2025. VAI is the second-best outcome in the USFDA's three-tier classification system, meaning the facility is broadly compliant with current Good Manufacturing Practices with no regulatory action required. This is a follow-up to Cipla's earlier intimation dated 20th February 2025 about the same inspection.
Positive for shareholders — the favorable VAI classification removes regulatory uncertainty around this facility and confirms continued operations without USFDA restrictions. Any minor observations can be voluntarily addressed by the company without penalty.